Agenda. Vigmed fundamentals. Sales & distribution. Product status. Partners. Global perspectives. Financial figures

Size: px

Start display at page:

Download "Agenda. Vigmed fundamentals. Sales & distribution. Product status. Partners. Global perspectives. Financial figures"

Abraham Ray
5 years ago
Views:

2 Agenda Vigmed fundamentals Sales & distribution Product status Partners Global perspectives Financial figures 2

Needlestick injuries inflict anxiety, infections and fatalities on a huge number of

3 Over 2,000,000 reported needlestick injuries occur every single year in Europe & US. Needlestick injuries are the most common occupational hazard in healthcare. Needlestick injuries inflict anxiety, infections and fatalities on a huge number of healthcare workers every year. The cost for society and for the individual afflicted is very high. 3

The strong heritage and competence of Vigmed and a focused mind-set are cornerstones in the formula for success In 1921 the med-tech company Viggo AB was established in Helsingborg, Sweden They

4 The strong heritage and competence of Vigmed and a focused mind-set are cornerstones in the formula for success In 1921 the med-tech company Viggo AB was established in Helsingborg, Sweden They launched their mega success, the I.V. catheter called Venflon in 1968 which remains until today a golden standard in most of the world Following the launch, Helsingborg built up its reputation as the European centre for I.V. catheters The Venflon production was moved by BD, who had acquired Viggo AB, to Asia in 2010/11, leaving a pool of talent in Helsingborg Our formula for success comes from combining the world class knowledge in the Helsingborg area with a focused mind-set of former Coloplast employees Venflon is a trademark of Becton Dickinson 4

5 The Vigmed story underlying market drivers Need Two million reported needlestick injuries per year in EU and US, plus more than one million unreported injuries The cost for society and for the individual afflicted is very high Supportive legislation In EU, safety devices are mandatory by law as of May 11, 2013 (EU Council Directive 2010/32 of May 10, 2010) In the USA, Needlestick Safety and Prevention Act (NSPA), Passed by the Congress in year 2000 Corresponding legislative measures are under way in several other geographies, supporting Vigmed s long-term growth story Large and growing market Total global market for Vigmed products that has been launched in 2014 and are planned for launch in 2015 is SEK 8 billion (with a safety penetration of between 20 95% depending on the segment) In addition, the global market potential for Vigmed projects under development are above SEK 25 billion 5

The Vigmed story unique competencies and business model Unique competencies A large part of Vigmed s knowledge base within R&D, automation, sales and marketing comes from individuals having a history

6 The Vigmed story unique competencies and business model Unique competencies A large part of Vigmed s knowledge base within R&D, automation, sales and marketing comes from individuals having a history in Viggo AB and the former Becton Dickinson operations in Helsingborg Strong patent portfolio Vigmed holds more than 15 patent families that are structured around 3 innovation platforms Each platform allows for product development in several existing product categories All innovation platforms offer several best in class product opportunities Controlled outsourcing / capital efficiency Supply chain, quality assurance and customer service partner MBH International A/S Contract Manufacturer (CM) for CLiP - Hindustan Syringes & Medical Devices Ltd. CM for SWiNG AB Euroform CM for our new product line SWiTCH AMB Industri AB Unique distribution set-up / sales channels With dominant competitors selling direct to hospitals, even the strongest local distributors have been cut out of the market this provides Vigmed with a unique opportunity to leverage distributors Carefully selected local distributors have the ability to compete with leading industry players and distributors have already started to receive re-orders 6

7 Agenda Vigmed fundamentals Sales & distribution Product status Partners Global perspectives Financial figures 7

At present we have sales in 11 countries and distribution agreements in 14 Vigmed s present distribution partners: CODAN - Sweden CODAN - Denmark CODAN - Norway CODAN - France CODAN - Austria Vygon

8 At present we have sales in 11 countries and distribution agreements in 14 Vigmed s present distribution partners: CODAN - Sweden CODAN - Denmark CODAN - Norway CODAN - France CODAN - Austria Vygon Germany Werfen Group/ Izasa Hospital - Spain Werfen Group/ Medicinália Cormédica - Portugal Mediq Switzerland Mavrogenis - Greece Medival / Nannini / Medi.Ca - Italy Aquilant, United Drug - Ireland Icepharma Iceland Device Technologies Ltd AUS/NZ Additional contracts currently under negotiation 8

9 Sales development in Q is up 124% vs. Q and 35% vs. full year 2014, but lower than expectations due to Vigclip issues in February in Q2'14 Q3'14 Q4'14 Q1'15 The Vigclip issues resulted in a replacement campaign and consequently, reduced sales The Vigclip issues will reduce sales until we have a robust design. Updated products will be launched during 2 nd half of 2015, starting in July Launch of obturators will increase our opportunities in DE, FR and SF significantly during 1 st half of

10 Agenda Vigmed fundamentals Sales & distribution Product status Partners Global perspectives Financial figures 10

11 Vigmed s current assortment Infusion Injection CLiP Ported CLiP Neo SWiNG Automatic passive safety no action required by user Precise tip configuration Available in polyurethane and FEP Transparently fast blood indication Ultra sharp and polished Automatic passive safety no action required by user Full familiar control Virtually friction free Notched for fast visual blood indication Ultra sharp and polished Activated automatic safety No way out for the needle once its trapped Clear line of sight Goodbye to dead space Wide range protection all the way up to 50 mm 11

12 Updated CLiP line will be launched during 2 nd half of 2015, beginning in July with CLiP Neo Withdrawal force Decoupling force Safety removal force Maximum Withdrawal Force Decoupling Force Safety Removal Force frequency (#) FMWF FDF FSRF Safety margin for Premature decoupling Safety margin for Non-safety removal force (N) 12

47% of injuries occur due to lack of automatically protected devices When needlestick injuries occur SWiNG Unique Selling Proposition A project born out of a speed-to-market argument/need

13 47% of injuries occur due to lack of automatically protected devices When needlestick injuries occur SWiNG Unique Selling Proposition A project born out of a speed-to-market argument/need Planned launch April/May 2014 Machine delivery postponed three times, and still no final date set Limited financial consequences for 2015 Source: ANA (American nurses association) study

Vigmed s future assortment Infusion Injection Artery CLiP Ported CLiP Neo

configuration Available in polyurethane and FEP Transparently fast blood

required by user Full familiar control Virtually friction free Notched for

safety No way out for the needle once its trapped Clear line of sight Goodbye

arterial safety solution Wider assortment than existing non-safety solutions

14 Vigmed s future assortment Infusion Injection Artery CLiP Ported CLiP Neo SWiNG SWiTCH Automatic passive safety no action required by user Precise tip configuration Available in polyurethane and FEP Transparently fast blood indication Ultra sharp and polished Automatic passive safety no action required by user Full familiar control Virtually friction free Notched for fast visual blood indication Ultra sharp and polished Activated automatic safety No way out for the needle once its trapped Clear line of sight Goodbye to dead space Wide range protection all the way up to 50 mm First ever arterial safety solution Wider assortment than existing non-safety solutions Automatic passive safety no action required by user Flow switch full control Flashback chamber Ultra sharp needle 14

15 Agenda Vigmed fundamentals Sales & distribution Product status Partners Global perspectives Financial figures 15

16 Established Partnerships According to the concept of Controlled Outsourcing In addition to our Indian partner, HMD, we have established expandable partnerships with local Scandinavian companies such as: - AB Euroform, Motala - AMB Industri AB, Emmaboda 16

The future: Focus on Europe (MDD) & Growth Regions The safety legislation of EU and US determines our focus, adding western countries who adopt a similar legislation as Australia and New Zealand.

17 The future: Focus on Europe (MDD) & Growth Regions The safety legislation of EU and US determines our focus, adding western countries who adopt a similar legislation as Australia and New Zealand. East Asia, International Donors and countries being served by Indian partner are other markets in focus Launch plans W. Europe AUS, NZ, UK, BX, SF Individual EEU countries USA & China/East Asia MDD/CE-Mark FDA / CFDA clearance approval 17

18 Agenda Vigmed fundamentals Sales & distribution Product status Partners Global perspectives Financial figures 18

19 Income statement (Group) ksek Q Q Net Sales Capitalized development costs Raw materials and consumables Other external costs Employee costs Depreciations and write-downs Other operating costs 17 6 Operating profit/loss Net financial income/expense Profit/loss after financial items Number of shares (weighted average in period) Profit/loss per share -0,21-0,15 19

20 Cash flow analysis (Group) ksek Q Q Net cash flow from op. act. before changes in work. capital Changes in working capital Net cash flow from operating activities Investments tangible assets Investments intangible assets Net cash flow from investing activities Issue of new shares - - Share options 14/ Net cash flow from financing activities Cash flow for the period Cash & cash equivalents at the beginning of the period Cash & cash equivalents at the end of the period

21 Key figures Group Q Q Net Sales (ksek) Operating profit/loss (ksek) Cash & cash equivalents (ksek) at closing day Equity capital (ksek) at closing day Solidity at closing day 79,6% 89,7% Total assets (ksek) at closing day Profit/loss per share -0,21-0,15 Share price at closing day (SEK) 8,90 20,40 21

22 22 Thank you

FINANCIAL INFORMATION FOR JANURAY SEPTEMBER IN BRIEF

FINANCIAL INFORMATION FOR JANURAY SEPTEMBER IN BRIEF Interim Report January 1 September 30, 2015 JANUARY - SEPTEMBER IN BRIEF Vigmed took over the supply chain as per September 30 from the Danish partner, MBH A/S. In September Vigmed was granted CE-mark